Cancer in Low- and Middle-Income Countries: An Economic Overview

Abstract

No AccessNov 2015Cancer in Low- and Middle-Income Countries: An Economic OverviewAuthors/Editors: Susan Horton and Cindy L. GauvreauSusan Horton and Cindy L. Gauvreauhttps://doi.org/10.1596/978-1-4648-0349-9_ch16AboutView ChaptersFull TextPDF (0.2 MB) ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinked In Abstract: Reviews the economics in health care system design and implementation by looking at patterns of cancer care resources across countries for surgery, radiotherapy, medications, laboratories and pathology, cancer registries, skilled medical personnel, health insurance and international partnerships. Cost-effectiveness of interventions is discussed for six types of cancers: cervical, breast, childhood, colon, liver, and oral. The dearth of literature on cost-effectiveness in low- and middle-income countries (LMICs) points out the need for more studies, especially for surgery which is considered the cornerstone of cancer treatments. Future economics work on cancer is to cost out the ingredients required for the priority interventions, such that costs of resource-appropriate care can be estimated in individual countries. ReferencesAballéa, S, A Boler, A Craig, and H Wasan. 2007. “An economic evaluation of oxaliplatin for the Adjuvant Treatment of Colon Cancer in the United Kingdom.” European Journal of Cancer 43 (11): 1687–93. CrossrefGoogle ScholarArmstrong, K, T M Chen, D Albert, T C Randall, and J S Schwartz. 2001. “Cost-Effectiveness of Raloxifene and Hormone Replacement Therapy in Postmenopausal Women: Impact of Breast Cancer Risk.” Obstetrics Gynecology 98 (6): 996–1003. CrossrefGoogle ScholarAvksentyeva, M 2010. “Colorectal Cancer in Russia.” European Journal of Health Economics 1: S91–S98. CrossrefGoogle ScholarBeutels, P 2001. “Economic Evaluations of Hepatitis B Immunization: A Global Review of Recent Studies (1994–2000).” Health Economics 10 751–74. CrossrefGoogle ScholarBhakta, N, A L C Martiniuk, S Gupta, and S C Howard. 2013. “The Cost-Effectiveness of Treating Paediatric Cancer in Low-Income and Middle-Income Countries: A Case-Study Approach Using Acute Lymphocytic Leukaemia in Brazil and Burkitt Lymphoma in Malawi.” Archives of Disease in Children 98 (2): 155–60. CrossrefGoogle ScholarCameron, D A, D R Camidge, J Oyee, and M Hirsch. 2008. “Economic Evaluation of Fulvestrant as an Extra Step in the Treatment Sequence for ER-Positive Advanced Breast Cancer.” British Journal of Cancer 99 (12): 1984–90. CrossrefGoogle ScholarCampos, N G, J J Kim, P E Castle, J Ortendahl, and M O’Shea others. 2012. “Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa.” International Journal of Cancer 130 (11): 2672–84. CrossrefGoogle ScholarCommission on Macroeconomics and Health. 2001. WHO. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Google ScholarCurado, M P, B Edwards, H R Shim, H Storm, and J Ferlay others, eds. 2007. Cancer Incidence in Five Continents, vol. IX. Scientific Publications 160. Lyon: International Agency for Research on Cancer. Google Scholarde Lima Lopes, G 2011. “Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore.” BMC Cancer 11 178–85. CrossrefGoogle Scholarde Verteuil, R M, R A Hernández, and L Vale. 2007. “Economic Evaluation of Laparoscopic Surgery for Colorectal Cancer.” International Journal of Technology Assessment in Health Care 23 (4): 464–72. CrossrefGoogle ScholarDedhia, R C, K J Smith, J T Johnson, and M Roberts. 2011. “The Cost-Effectiveness of Community-Based Screening for Oral Cancer in High-Risk Males in the United States: A Markov Decision Analysis Approach.” Laryngoscope 121 (5): 952–60. CrossrefGoogle ScholarDelea, T E, J Karnon, O Sofrygin, S K Thomas, N L Papo, and V Barghout. 2007. “Cost-effectiveness of Letrozole versus Tamoxifen as Initial Adjuvant Therapy in Hormone-receptor-positive Postmenopausal Women with Early-stage Breast Cancer.” Clinical Breast Cancer 7 (8): 608–18. CrossrefGoogle ScholarDesch, C E, B E Hillner, T J Smith, and S M Retchin. 1993. “Should the Elderly Receive Chemotherapy for Node-Negative Breast Cancer? A Cost-Effectiveness Analysis Examining Total and Active Life-Expectancy Outcomes.” Journal of Clinical Oncology 11 (4): 777–82. Google ScholarDranitsaris, G, S Verma, and M Trudeau. 2003. “Cost Utility Analysis of First-line Hormonal Therapy in Advanced Breast Cancer: Comparison of Two Aromatase Inhibitors to Tamoxifen.” American Journal of Clinical Oncology 26(3):289–96. Google ScholarDrummond, M F, M J Schulpher, G W Torrance, D J O’Brien, and G L Stoddart. 2005. Methods for the Economic Evaluation of Health Care Programmes. 3rd edition. New York: Oxford University Press. Google ScholarEssers, B A, S C Seferina, V C Tjan-Heijnen, J L Severens, and A Novák others. 2010. “Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands.” Value in Health 13 (4): 375–80. CrossrefGoogle ScholarFonseca, M, G T B Araújo, and E D Saad. 2009. “Cost-Effectiveness of Anastrozole, in Comparison with Tamoxifen, in the Adjuvant Treatment of Early Breast Cancer in Brazil.” Revista Da Associação Medica Brasileira 55 410–15. CrossrefGoogle ScholarFunk, L M, T G Weiser, W R Berry, S R Lipsitz, and A F Merry others. 2010. “Global Operating Theatre Distribution and Pulse Oximetry Supply: An Estimation from Reported Data.” Lancet 376 (9746): 1055–61. CrossrefGoogle ScholarGil, J M, C Rubio-Terres, C A Del, P Gonzalez, and F Canorea. 2006. “Pharmacoeconomic Analysis of Adjuvant Therapy with Exemestane, Anastrozole, Letrozole or Tamoxifen in Postmenopausal Women with Operable and Estrogen Receptor-Positive Breast Cancer” Clinical Transl Oncology 8 (5): 339–48. CrossrefGoogle ScholarGinsberg, G M, J A Lauer, S Zelle, S Baetan, and R Baltussen. 2012. “Cost Effectiveness of Strategies to Combat Breast, Cervical, and Colorectal Cancer in sub-Saharan Africa and South East Asia: Mathematical Modelling Study.” British Medical Journal 344: eb14. doi:10.1136/bmj.e614. CrossrefGoogle ScholarGoldie, S J, L Gaffikin, J D Goldhaber-Fiebert, A Gordillo-Tobar, and C Levin others. 2005. “Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries.” New England Journal of Medicine 353 2158–68. CrossrefGoogle ScholarGreenberg, D, C Earle, C H Fang, A Eldar-Lissai, and P J Neumann. 2010. “When Is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology.” Journal of the National Cancer Institute 102 (2): 82–88. CrossrefGoogle ScholarHayes, J L and P Hansen. 2007. “Is Laparoscopic Colectomy for Cancer Cost-Effective Relative to Open Colectomy?” Australia and New Zealand Journal of Surgery 77 (9): 782–86. CrossrefGoogle ScholarHedden, L, S O’Reilly, C Lohrisch, S Chia, and C Speers others. 2012. “Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer.” Oncologist 17 (2): 164–71. CrossrefGoogle ScholarHillner, B E and T J Smith. 1991. “Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer. A Decision-Analysis Model.” New England Journal of Medicine 324 (3): 160–68. CrossrefGoogle ScholarHillner, B E and T J Smith. 1993. “Assessing the Cost Effectiveness of Adjuvant Therapies in Early Breast Cancer Using a Decision Analysis Model.” Breast Cancer Research and Treatment 25 (2): 97–105. CrossrefGoogle ScholarIAEA (International Atomic Energy Authority). 2013. “Radiotherapy Availability.” Programme of Action for Cancer Therapy (PACT), Programme Office. http://cancer.iaea.org/agart.asp. Google ScholarIshiguro, H, M Kondo, S L Hoshi, M Takada, and S Nakamura others. 2010. “Economic Evaluation of Intensive Chemotherapy with Prophylactic Granulocyte Colony-Stimulating Factor for Patients with High-Risk Early Breast Cancer in Japan.” Clinical Therapeutics 32 (2): 11–26. CrossrefGoogle ScholarKarnon, J, R Delea, S R Johnston, R Smith, J Brandman, and J Sung others 2003. “Cost-effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: the UK Perspective. Pharmacoeconomics 24 (3): 237–50. CrossrefGoogle ScholarKim, J J, K E Kobus, M Diaz, V Van Minh, and S J Goldie. 2008. “Exploring the Cost-Effectiveness of HPV Vaccination in Vietnam: Insights for Evidence-Based Cervical Cancer Prevention Policy.” Vaccine 26 4015–24. CrossrefGoogle ScholarKhlangwiset, P and F Wu. 2010. “Costs and Efficacy of Public Health Interventions to Reduce Aflatoxin-induced Human Disease.” Food Additives and Contaminants Part A Chemical Analysis, Control of Exposure and Risk Assessment 27(7): 998–1014. Google ScholarKnaul, F M, E E González-Pier, O Gómez-Dantés, D García-Junco, and H Arreola-Ornelas others. 2012. “The Quest for Universal Health Coverage: Achieving Social Protection for All in Mexico.” Lancet 350 1259–79. CrossrefGoogle ScholarLee, S Y, S H Jeong, Y N Kim, J Kim, and D R Kang others. 2009. “Cost-Effective Mammography Screening in Korea: High Incidence of Breast Cancer in Young Women.” Cancer Science 100: 1105–1111. CrossrefGoogle ScholarLevin, C E, J Sellors, J -F Shi, L Ma, Y -L Qiao, J Ortendahl, M K H O’Shea, and S J Goldie. 2010. “Cost-effectiveness Analysis of Cervical Cancer Prevention based on a Rapid Human Papillomavirus Screening Test in a High-Risk Region of China.” International Journal of Cancer 127 1404–11. CrossrefGoogle ScholarLiberato, N L, M Marchetti, and G Barosi. 2007. “Cost-Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” Journal of Clinical Oncology. 25(6):625–33. CrossrefGoogle ScholarLuo, X Q, Z Y Ke, L B Huang, X Q Guan, and Y C Zhang others. 2009. “Improved Outcome for Chinese

Keywords

Related Publications